Increase of vertebral density by combination therapy with pulsatile 1-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients.
Combination therapy with the biologically active (1-38) human parathyroid hormone peptide and calcitonin using pulsatile and sequential activation of the skeleton for 14 months in patients with low-turnover osteoporosis resulted in an increase in trabecular bone mass. These favorable responses were observed without any significant changes in cortical (forearm) bone mass content.
Hesch
R D
RD
Abteilung für Klinische Endokrinologie, Medizinische Hochschule Hannover, Federal Republic of Germany.
Busch
U
U
Prokop
M
M
Delling
G
G
Rittinghaus
E F
EF
D000281:Administration, Intranasal / Q000379:methods; D000328:Adult; D000368:Aged; D002116:Calcitonin / Q000008:administration & dosage / Q000627:therapeutic use*; D002574:Cervical Vertebrae / Q000473:pathology*; D004359:Drug Therapy, Combination / Q000379:methods; D005260:Female; D006801:Humans; D008159:Lumbar Vertebrae / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy* / Q000473:pathology; D010281:Parathyroid Hormone / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000627:therapeutic use*; D013904:Thoracic Vertebrae / Q000473:pathology*
D010281:Parathyroid Hormone; D010446:Peptide Fragments; C035747:parathyroid hormone (1-38); D002116:Calcitonin